Correction to: Leukemia https://doi.org/10.1038/s41375-021-01496-8, published online 07 February 2022
We have noticed a minor error in figure 3. The number at risk of ponatinib group and dasatinib group were swapped. Below is the corrected figure.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sasaki, Y., Kantarjian, H.M., Short, N.J. et al. Correction: Genetic correlates in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with Hyper-CVAD plus dasatinib or ponatinib. Leukemia 36, 1448 (2022). https://doi.org/10.1038/s41375-022-01568-3
Published:
Issue date:
DOI: https://doi.org/10.1038/s41375-022-01568-3
